Showing results (71-80 of 177) with videos related to

Sort By:
Pageof 18
The Lancet. Neurology|June 23, 2023
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trialJohn R Corboy, Robert J Fox, Ilya Kister, et al.
Neurology|January 9, 2013
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspectsAlireza Minagar, Michael H Barnett, Ralph H B Benedict, et al.
Neurology|February 3, 2017
Serum neurofilament is associated with progression of brain atrophy and disability in early MSJens Kuhle, Bardia Nourbakhsh, Donna Grant, et al.
Archives of Neurology|December 14, 2011
Magnetic resonance techniques in multiple sclerosis: the present and the futureMassimo Filippi, Maria A Rocca, Nicola De Stefano, et al.
Multiple Sclerosis and Related Disorders|February 10, 2016
Longitudinal associations between MRI and cognitive changes in very early MSBardia Nourbakhsh, Julia Nunan-Saah, Amir-Hadi Maghzi, et al.
Annals of Neurology|January 13, 2018
Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout diseaseChristina J Azevedo, Steven Y Cen, Sankalpa Khadka, et al.
Neurology|July 13, 2012
A randomized trial of stress management for the prevention of new brain lesions in MSDavid C Mohr, Jesus Lovera, Ted Brown, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2017
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studiesMark S Freedman, Jerry S Wolinsky, Giancarlo Comi, et al.
The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairmentJeffrey A Cohen, Michelle H Cameron, Myla D Goldman, et al.
Pageof 18